Compare FATE & ACR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FATE | ACR |
|---|---|---|
| Founded | 2007 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.6M | 148.3M |
| IPO Year | 2013 | N/A |
| Metric | FATE | ACR |
|---|---|---|
| Price | $1.21 | $19.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 2 |
| Target Price | $3.92 | ★ $24.50 |
| AVG Volume (30 Days) | ★ 1.8M | 20.9K |
| Earning Date | 03-04-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.65 |
| EPS | N/A | ★ 0.95 |
| Revenue | $7,137,000.00 | ★ $88,952,000.00 |
| Revenue This Year | N/A | $3.67 |
| Revenue Next Year | N/A | $1.87 |
| P/E Ratio | ★ N/A | $20.08 |
| Revenue Growth | N/A | ★ 14.87 |
| 52 Week Low | $0.66 | $15.64 |
| 52 Week High | $1.94 | $24.61 |
| Indicator | FATE | ACR |
|---|---|---|
| Relative Strength Index (RSI) | 53.84 | 33.41 |
| Support Level | $1.17 | $18.64 |
| Resistance Level | $1.32 | $20.82 |
| Average True Range (ATR) | 0.08 | 0.50 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 53.33 | 30.32 |
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
ACRES Commercial Realty Corp is a commercial real estate investment trust that focuses on originating, holding and managing commercial real estate (CRE) mortgage loans and equity investments in commercial real estate properties through direct ownership and joint ventures. The company invests in commercial real-estate-related assets, including whole loans, A notes, B notes, mezzanine loans, and mortgage-related securities, as well as commercial finance assets, which include other asset-backed securities, senior secured corporate loans, equipment leases and notes, trust preferred securities, debt tranches of collateralize debt obligations, and private equity investments mainly issued by financial institutions.